Fmr LLC Sells 1,157,476 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

FMR LLC trimmed its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 20.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,591,267 shares of the specialty pharmaceutical company’s stock after selling 1,157,476 shares during the period. FMR LLC owned 7.61% of Jazz Pharmaceuticals worth $569,134,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in JAZZ. Vanguard Group Inc. lifted its stake in shares of Jazz Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 4,882,984 shares of the specialty pharmaceutical company’s stock worth $820,975,000 after purchasing an additional 23,400 shares during the period. Vanguard Group Inc lifted its stake in shares of Jazz Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc now owns 4,882,984 shares of the specialty pharmaceutical company’s stock worth $820,975,000 after purchasing an additional 23,400 shares during the period. BlackRock Inc. lifted its stake in shares of Jazz Pharmaceuticals by 2.7% during the 3rd quarter. BlackRock Inc. now owns 4,490,714 shares of the specialty pharmaceutical company’s stock worth $755,024,000 after purchasing an additional 118,634 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Jazz Pharmaceuticals by 3.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,912,173 shares of the specialty pharmaceutical company’s stock worth $321,494,000 after purchasing an additional 56,291 shares during the period. Finally, Bank of New York Mellon Corp lifted its stake in shares of Jazz Pharmaceuticals by 14.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,690,385 shares of the specialty pharmaceutical company’s stock worth $284,205,000 after purchasing an additional 207,954 shares during the period. 93.41% of the stock is owned by institutional investors.

In other Jazz Pharmaceuticals news, CFO Matthew P. Young sold 1,152 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $135.41, for a total value of $155,992.32. Following the transaction, the chief financial officer now owns 38,700 shares in the company, valued at $5,240,367. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Paul Treacy sold 874 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $139.50, for a total transaction of $121,923.00. The disclosure for this sale can be found here. Insiders have sold 11,668 shares of company stock worth $1,606,567 in the last quarter. Company insiders own 3.90% of the company’s stock.

Shares of NASDAQ:JAZZ opened at $138.39 on Tuesday. Jazz Pharmaceuticals PLC has a 52 week low of $113.52 and a 52 week high of $184.00. The company has a market capitalization of $7.82 billion, a price-to-earnings ratio of 11.31, a PEG ratio of 0.93 and a beta of 1.23. The company has a current ratio of 3.57, a quick ratio of 3.42 and a debt-to-equity ratio of 0.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $3.27 EPS for the quarter, beating the consensus estimate of $2.66 by $0.61. Jazz Pharmaceuticals had a net margin of 23.64% and a return on equity of 26.20%. The company had revenue of $476.46 million for the quarter, compared to analyst estimates of $459.48 million. During the same quarter last year, the business earned $2.95 earnings per share. Jazz Pharmaceuticals’s revenue was up 9.2% compared to the same quarter last year. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 13.19 EPS for the current year.

JAZZ has been the subject of a number of research analyst reports. Cowen restated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, February 13th. Cantor Fitzgerald reiterated a “buy” rating and issued a $185.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, February 12th. Wells Fargo & Co reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Sunday, December 23rd. Oppenheimer set a $180.00 price target on Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, December 23rd. Finally, BidaskClub upgraded Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, December 18th. One analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $184.53.

COPYRIGHT VIOLATION NOTICE: “Fmr LLC Sells 1,157,476 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)” was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/16/fmr-llc-sells-1157476-shares-of-jazz-pharmaceuticals-plc-jazz.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: Net Margin – Understanding the Different Kinds of Profit

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.